Jolley Asset Management LLC Has Lowered Its Position in Glaxo Smithkline Ads (GSK) by $3.24 Million

April 17, 2018 - By Linda Rogers

GlaxoSmithKline plc (NYSE:GSK) Logo

Jolley Asset Management Llc decreased its stake in Glaxo Smithkline Ads (GSK) by 99.7% based on its latest 2017Q4 regulatory filing with the SEC. Jolley Asset Management Llc sold 92,663 shares as the company’s stock rose 9.28% while stock markets declined. The institutional investor held 280 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $10,000, down from 92,943 at the end of the previous reported quarter. Jolley Asset Management Llc who had been investing in Glaxo Smithkline Ads for a number of months, seems to be less bullish one the $96.80 billion market cap company. The stock increased 0.21% or $0.0866 during the last trading session, reaching $40.5566. About 1.33 million shares traded. GlaxoSmithKline plc (NYSE:GSK) has declined 10.07% since April 17, 2017 and is downtrending. It has underperformed by 21.62% the S&P500.

Analysts await GlaxoSmithKline plc (NYSE:GSK) to report earnings on April, 25. They expect $0.71 earnings per share, up 14.52 % or $0.09 from last year’s $0.62 per share. GSK’s profit will be $1.69 billion for 14.28 P/E if the $0.71 EPS becomes a reality. After $0.72 actual earnings per share reported by GlaxoSmithKline plc for the previous quarter, Wall Street now forecasts -1.39 % negative EPS growth.

GlaxoSmithKline plc (NYSE:GSK) Ratings Coverage

Among 6 analysts covering GlaxoSmithKline (NYSE:GSK), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. GlaxoSmithKline had 7 analyst reports since October 26, 2017 according to SRatingsIntel. The firm has “Hold” rating by Cowen & Co given on Monday, December 11. As per Monday, November 27, the company rating was upgraded by UBS. Barclays Capital upgraded the stock to “Buy” rating in Tuesday, January 16 report. On Wednesday, April 4 the stock rating was upgraded by BNP Paribas to “Buy”. On Thursday, October 26 the stock rating was downgraded by Bank of America to “Hold”. On Wednesday, February 14 the stock rating was maintained by Cowen & Co with “Hold”.

GlaxoSmithKline plc (NYSE:GSK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: